Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.

By Kamal Choudhury (Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Health secretary Robert F. Kennedy Jr. this week is sowing doubt about the safety and efficacy of some vaccines — beyond the ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

In today's Morning Rounds newsletter, RFK Jr.'s latest theory about vaccines, how sweeping FDA layoffs could impact drug ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.

The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

BofA lowered the firm’s price target on Novavax (NVAX) to $10 from $12 and keeps a Neutral rating on the shares. Shares are sliding over 21% ...